# Ji‐Youn Han

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ji-youn-han/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,653 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 70 |
| i10-index | 196 |
| Last Known Institution | Baekseok Culture University |
| OpenAlex ID | https://openalex.org/A5023055777 |
| ORCID iD | https://orcid.org/0000-0001-5033-0006 |
| Works | 492 |

## Researcher papers

Showing 12 of 15.

- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations](https://scholariq.org/papers/tepotinib-in-non-small-cell-lung-cancer-with-i-met-i-exon-14-skipping-mutations/)
- [First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung](https://scholariq.org/papers/first-signal-first-line-single-agent-iressa-versus-gemcitabine-and-cisplatin/)
- [Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/osimertinib-for-pretreated-egfr-thr790met-positive-advanced-non-small-cell-lung/)
- [Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://scholariq.org/papers/amivantamab-in-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study](https://scholariq.org/papers/osimertinib-plus-savolitinib-in-patients-with-egfr-mutation-positive-met/)
- [Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-alk-inhibitor-naive-advanced-alk-positive-nsclc/)
- [Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-advanced-alk-inhibitor-naive-alk-positive-non/)
- [Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis](https://scholariq.org/papers/osimertinib-versus-platinum-pemetrexed-for-patients-with-egfr-t790m-advanced/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Baekseok Culture University](https://scholariq.org/institutions/baekseok-culture-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.